Search

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

EHA ‘Excellence in Hematology’ Survey now online

Excellence in Hematology is created together. Would you help us out?

This week, we’re starting an important research endeavor – our ‘Excellence in hematology’ survey.

Read more

Hematology and oncology, pacemakers for EU HTA

EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).

Read more

Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

The Hague, Wednesday 18, November, 2020

The field of cell and gene therapy is one of the most…

Read more

Evidence and policy to ensure good clinical practice

Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA

Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…

Read more

EU funding approved for TOLERATE

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more